Estrella Immunopharma, Inc.
ESLA · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $44,017 | $38,721 | $59,300 | $58,497 |
| - Cash | $917 | $4,165 | $41 | $4,088 |
| + Debt | $0 | $0 | $499 | $0 |
| Enterprise Value | $43,100 | $34,556 | $59,758 | $54,409 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$8,846 | -$7,310 | -$687 | -$11 |
| % Margin | – | – | – | – |
| Net Income | -$8,848 | -$7,312 | -$996 | -$1,685 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.25 | -0.21 | -0.17 | -0.29 |
| % Growth | -19% | -23.5% | 41.4% | – |
| Operating Cash Flow | -$7,640 | -$16,068 | -$1,044 | -$1,442 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$7,640 | -$16,068 | -$1,044 | -$1,442 |